WilmerHale Reps Thermo Fisher Scientific in Agreement to Acquire Alfa Aesar

Download IconDownload Print IconPrint

WilmerHale Reps Thermo Fisher Scientific in Agreement to Acquire Alfa Aesar

Firm News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.

On June 25, Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals and part of Johnson Matthey Plc, for £256 million (approximately $405 million) in cash. 

Based in Heysham, United Kingdom, Alfa Aesar has 480 employees and operates in key research hubs in the United States, Germany, China, South Korea and India. The business generated sales of approximately £78 million (or $125 million) in 2014. The transaction, which is expected to be completed by the end of 2015, is subject to customary closing conditions, including regulatory approvals. Alfa Aesar will be integrated into Thermo Fisher's Laboratory Products and Services Segment.

WilmerHale represented longtime client Thermo Fisher in this transaction. The deal team was led by Partners Hal Leibowitz and Joe Wyatt and included Partners Joe Pillman, Keith Barnett, Robert Burke, Christian Crones, Belinda Juran, Amy Null, Laura Schneider, Holger Thomas and Kenneth Zhou; Counsels Ciara Baker, Olaf Weiß and Golo Weidmann; Senior Associate Andrew Stauber; and Associates Julie Fogarty and Tim Kulis.

Thermo Fisher's full press release is available on thermofisher.com.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel